Business Context and Reporting Period
Pluri Inc. (PLUR), a Nevada corporation headquartered in Haifa, Israel, filed this Form 8-K on January 29, 2025, reporting events occurring on January 23, 2025. The filing details a private placement offering and a strategic investment term sheet.
Key Financial Metrics and Transaction Details
- Private Placement Offering: The Company entered into a Securities Purchase Agreement for gross proceeds of approximately $6.5 million.
- Securities Issued:
- 1,383,948 Common Shares at $4.61 per share.
- Pre-Funded Warrants to purchase up to 26,030 Common Shares (exercise price $0.0001).
- Common Warrants to purchase up to 84,599 Common Shares (exercise price $5.568).
- Use of Proceeds: Working capital and general corporate purposes.
- Kokomodo Transaction: A binding term sheet was signed to acquire approximately 71% of Kokomodo Ltd. for $4.5 million, payable in Common Shares.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, or debt metrics. It is a current report regarding specific corporate events.
Material Changes and Corporate Actions
- Board Appointment: Mr. Alejandro Weinstein, the investor in the private placement, was appointed to the Board of Directors effective upon the closing of the Offering.
- Ownership Threshold: Mr. Weinstein's board seat is contingent on him holding at least 10% of the Company's issued and outstanding Common Shares.
- Transaction Status: The Offering is expected to close on or about January 31, 2025. The Kokomodo Transaction is subject to due diligence, definitive agreement execution, and shareholder approval.
Guidance, Risks, and Contingencies
- Contingent Investment: If the Kokomodo Transaction fails to close (excluding specific investor failures or undisclosed liabilities exceeding $500,000), the Company must purchase a portion of the Investor's Kokomodo shares for $1,000,000 and invest an additional $500,000 via a SAFE with a $5.5 million valuation cap.
- Regulatory Approvals: Both the Offering and the Kokomodo Transaction require shareholder approval and compliance with Nasdaq Capital Market rules.
- Forward-Looking Risks: Risks include failure to meet closing conditions, inability to negotiate final documentation, regulatory non-approval of products, clinical trial delays, and market competition.
Investor Verification Checklist
- Verify the closing of the $6.5 million private placement and the issuance of shares/warrants.
- Confirm the successful execution of the definitive agreement for the Kokomodo Ltd. acquisition.
- Monitor shareholder vote results required for the Kokomodo Transaction and the exercise of warrants.
- Review the final terms of the Kokomodo acquisition to ensure the $4.5 million valuation holds.
- Assess the impact of the new board member and the 19.99% beneficial ownership limitation on future capital raises.